Pradaxa finally wins English warfarin replacement race, despite appeal
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's Pradaxa (dabigataran) has now officially won the warfarin replacement race in England for preventing stroke and systemic embolism in patients with atrial fibrillation. NICE, the health technology appraisal institute for England and Wales, has today published final guidance recommending the drug after an appeal against the decision was dismissed.